LabGenomics USA Acquires Integrated Molecular Diagnostics (IMD) CLIA Labs
October 25, 2024
LabGenomics USA acquired Integrated Molecular Diagnostics (IMD) CLIA labs, expanding its U.S. footprint to four CLIA-certified laboratories and strengthening its molecular and oncology diagnostic capabilities. The deal broadens LabGenomics' geographic reach across the U.S. coasts and positions the company to launch new laboratory-developed tests (LDTs) and expand reimbursable services.
- Buyers
- LabGenomics USA
- Targets
- Integrated Molecular Diagnostics (IMD) CLIA labs
- Industry
- Healthcare Services
- Location
- California, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
LabGenomics USA LLC Acquires QDx Pathology
September 5, 2023
Healthcare Services
LabGenomics USA LLC, a subsidiary of South Korea–based LabGenomics Co., Ltd., has acquired QDx Pathology, a U.S. clinical and molecular pathology laboratory. The deal, signed in August 2023, is intended to accelerate LabGenomics' entry and expansion into the North American diagnostics market by combining QDx's lab services with LabGenomics' NGS-based molecular diagnostics capabilities.
-
Labcorp Acquires Personal Genome Diagnostics (PGDx)
February 21, 2022
Healthcare Services
Labcorp completed its acquisition of Personal Genome Diagnostics (PGDx), a cancer genomics company that develops liquid biopsy and tissue-based NGS products. Labcorp paid $450 million in cash at closing plus up to $125 million in performance-based milestones to expand its oncology genomics and liquid biopsy capabilities and accelerate access to precision diagnostics for clinical care and trials.
-
MLM Medical Labs Acquires MD Biosciences, Inc.
October 27, 2020
Healthcare Services
MLM Medical Labs, a Great Point Partners portfolio company, has acquired MD Biosciences, Inc., an Oakdale, Minnesota-based provider of preclinical, translational and clinical-phase contract research services. The deal expands MLM's U.S. footprint and adds immunohistochemistry, preclinical research and histopathology capabilities to its global laboratory platform as part of an integration with recent U.S. additions such as CirQuest Labs.
-
Canopy Biosciences Acquires Core Diagnostics
December 4, 2019
Biotechnology
Canopy Biosciences, a St. Louis-based multi-omic services company backed by Ampersand Capital Partners, has acquired Core Diagnostics, a California CLIA-certified biomarker analysis laboratory. The acquisition gives Canopy CLIA-certified laboratory capabilities to offer its multi-omic immune profiling services to clinical as well as preclinical and translational customers.
-
Quest Diagnostics Acquires Labtech Diagnostics
December 14, 2021
Healthcare Services
Quest Diagnostics has acquired substantially all assets of Labtech Diagnostics, an independent clinical diagnostic laboratory based in Anderson, South Carolina. The acquisition brings Labtech into Quest’s national laboratory network — Quest’s first full-service laboratory in South Carolina — and expands Quest’s diagnostic capabilities and presence across the Southeast.
-
JMD Properties, Inc. Acquires Stella Diagnostics
September 2, 2020
Biotechnology
JMD Properties, Inc. announced the acquisition of Stella Diagnostics, LLC via a preferred stock transaction and will change its corporate name to Stella Diagnostics, Inc. The deal positions the public company to pivot into the molecular diagnostics / biotech sector to commercialize Stella’s oncology-focused assays for esophageal disease.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.